Sign Up to like & get
recommendations!
0
Published in 2018 at "American journal of ophthalmology"
DOI: 10.1016/j.ajo.2018.04.008
Abstract: PURPOSE The Medicare cost savings from the use of bevacizumab in the United States for the treatment of exudative age-related macular degeneration (AMD) were estimated by replacing the use of bevacizumab with ranibizumab and aflibercept.…
read more here.
Keywords:
savings use;
use bevacizumab;
exudative age;
treatment ... See more keywords